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Protein Kinase G I (PKGI) has been implicated as a nega-
tive regulator of pathologic cardiac hypertrophy [1,2],
though the specific molecular mechanisms involved are
unknown. To test the hypothesis that PKGIα negatively
regulates cardiac hypertrophy, we characterized the car-
diac phenotype in mice homozygous for a leucine zipper
mutant (LZM) form of PKGIα in which critical amino
acids in the N-terminal LZ motif have been substituted to
disrupt PKGIα LZ binding to specific downstream effector
proteins. We characterized the hearts of these LZM mice
morphologically, by echocardiography and invasive
hemodynamics in the unstressed state, and following
pressure overload-induced cardiac hypertrophy. In the
unstressed state, male PKG Iα LZM mice develop progres-
sive left ventricular hypertrophy (LV mass/ tibia length)
compared with wild type (WT) littermates with LV mass
12.3% greater at 30 weeks of age (p = 0.05, n = 10 WT, 9
LZM); and 27% greater at 60 weeks of age (p < 0.001, n =
5 WT, 13 LZM). Compared with age matched WT mice,
the hearts of 30 week old PKGIα mutants are hypercon-
tractile with decreased end systolic diameter (2.25 mm
WT vs 1.95 mm LZM, p = 0.02) and increased fractional
shortening (36.9% WT vs 42.2% LZM, p = 0.03) on
echocardiography (n = 9 wt, 9 LZM). Invasive hemody-
namic assessment demonstrates that LZM mice also have
increased left ventricular systolic pressure (107.0 mmHg
WT vs 120.7 mmHg LZM, p = 0.04), developed pressure
(107.5 mmHg WT vs 119.2 mmHg LZM, p = 0.05), and LV
dP/dt max (8972 mmHg/s WT vs 9802 mmHg/s LZM, p =
0.13).
To evaluate the response to hemodynamic stress, cardiac
hypertrophy was induced by transaortic constriction
(TAC) in 10–12 week old male WT (n = 21) and LZM (n
= 15) mice. TAC resulted in striking and early mortality in
the LZM mice (60%) compared to the WT (19%) mice at
21 days post procedure (p = 0.008), with evidence of
accelerated LV hypertrophy in the mice that died early (LV
mass/tibia length 9.8 mg/mm in the early LZM deaths vs
7.2 mg/mm in WT 21 day survivors, p < 0.001). Addition-
ally, the LZM early deaths had evidence of congestive
heart failure with increased right ventricular mass (RV
mass/ tibia length 1.8 mg/mm in LZM early deaths vs 1.2
mg/mm in WT 21 day survivors, p < 0.05), and increased
lung mass (23.1 mg/mm LZM early deaths vs 12.5 mg/
mm in WT 21 day survivors, p < 0.005). These findings
support that the N-terminal LZ domain of PKGIα is
required for PGKIα-mediated suppression of cardiac
hypertrophy in both unstressed hearts and those exposed
to pressure overload. The early mortality following TAC in
the LZM mice also supports a critical role for PKGIα in
attenuating pathologic cardiac remodeling, identifying
PKGIα as an attractive candidate therapeutic target for pre-
vention of cardiac hypertrophy and failure.
from 3rd International Conference on cGMP Generators, Effectors and Therapeutic Implications
Dresden, Germany. 15–17 June 2007
Published: 25 July 2007
BMC Pharmacology 2007, 7(Suppl 1):S26 doi:10.1186/1471-2210-7-S1-S26
<supplement> <title> <p>3<sup>rd </sup>International Conference on cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-7-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/7/S1/S26
© 2007 Blanton et al; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
BMC Pharmacology 2007, 7(Suppl 1):S26 http://www.biomedcentral.com/1471-2210/7/S1/S26Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright




1. Fiedler B, Lohmann SM, Smolenski A, Linnemueller S, Pieske B, Schro-
der F, Molkentin JD, Drexler H, Wollert KC: Inhibition of cal-
cineurin-NFAT hypertrophy signalling by cGMP-dependent
protein kinase type I in cardiac myocytes.  Proc Natl Acad Sci
2002, 99:11363-11368.
2. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER,
Bedja D, Gabrielson KL, Wang Y, Kass DA: Chronic inhibition of
cyclic GMP phosphodiesterase 5A prevents and reverses car-
diac hypertrophy.  Nature Med 2005, 11:214-222.Page 2 of 2
(page number not for citation purposes)
